# GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms

> **NCT07306156** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhimin Zhai** · enrollment: 24 (estimated)

## Conditions studied

- EBV Associated Lymphoid Neoplasms

## Interventions

- **BIOLOGICAL:** GP350 CAR-T

## Key facts

- **NCT ID:** NCT07306156
- **Lead sponsor:** Zhimin Zhai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-10
- **Primary completion:** 2030-11-10
- **Final completion:** 2032-11-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306156, "GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07306156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*